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SH2B1 Enhances Insulin Sensitivity by Both Stimulating
the Insulin Receptor and Inhibiting Tyrosine
Dephosphorylation of Insulin Receptor Substrate
Proteins
David L. Morris, Kae Won Cho, Yingjiang Zhou, and Liangyou Rui
OBJECTIVE—SH2B1 is a SH2 domain-containing adaptor pro-
tein expressed in both the central nervous system and peripheral
tissues. Neuronal SH2B1 controls body weight; however, the
functions of peripheral SH2B1 remain unknown. Here, we stud-
ied peripheral SH2B1 regulation of insulin sensitivity and glucose
metabolism.
RESEARCH DESIGN AND METHODS—We generated TgKO
mice expressing SH2B1 in the brain but not peripheral tissues.
Various metabolic parameters and insulin signaling were exam-
ined in TgKO mice fed a high-fat diet (HFD). The effect of SH2B1
on the insulin receptor catalytic activity and insulin receptor
substrate (IRS)-1/IRS-2 dephosphorylation was examined using
in vitro kinase assays and in vitro dephosphorylation assays,
respectively. SH2B1 was coexpressed with PTP1B, and insulin
receptor–mediated phosphorylation of IRS-1 was examined.
RESULTS—Deletion of peripheral SH2B1 markedly exacerbated
HFD-induced hyperglycemia, hyperinsulinemia, and glucose intol-
erance in TgKO mice. Insulin signaling was dramatically impaired in
muscle, liver, and adipose tissue in TgKO mice. Deletion of SH2B1
impaired insulin signaling in primary hepatocytes, whereas SH2B1
overexpression stimulated insulin receptor autophosphorylation
and tyrosine phosphorylation of IRSs. Puriﬁed SH2B1 stimulated
insulin receptor catalytic activity in vitro. The SH2 domain of SH2B1
was both required and sufﬁcient to promote insulin receptor acti-
vation. Insulin stimulated the binding of SH2B1 to IRS-1 or IRS-2.
This physical interaction inhibited tyrosine dephosphorylation of
IRS-1 or IRS-2 and increased the ability of IRS proteins to activate
the phosphatidylinositol 3-kinase pathway.
CONCLUSIONS—SH2B1 is an endogenous insulin sensitizer. It
directly binds to insulin receptors, IRS-1 and IRS-2, and enhances
insulin sensitivity by promoting insulin receptor catalytic activity
and by inhibiting tyrosine dephosphorylation of IRS proteins.
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nsulin decreases blood glucose both by promoting
glucose uptake into skeletal muscle and adipose
tissue and by suppressing hepatic glucose produc-
tion. In type 2 diabetes, the ability of insulin to
reduce blood glucose is impaired (insulin resistance)
because of a combination of genetic and environmental
factors, resulting in hyperglycemia. Insulin resistance is
not only the hallmark but also a determinant of type 2
diabetes.
Insulin binds to and activates the insulin receptor.
Insulin receptor tyrosyl phosphorylates insulin receptor
substrates (IRS-1, -2, -3, and -4). IRS proteins, particularly
IRS-1 and IRS-2, initiate and coordinate multiple down-
stream pathways, including the phosphatidylinositol 3-ki-
nase/Akt pathway (1). Genetic deletion of IRS-1, IRS-2, or
Akt2 causes insulin resistance in mice, indicating that the
IRS protein/phosphatidylinositol 3-kinase/Akt2 pathway is
required for regulation of glucose homeostasis by insulin
(2–5). Insulin receptor and IRS proteins are negatively
regulated by various intracellular molecules, including
PTP1B, Grb10, Grb14, SOCS1, SOCS3, JNK, PKC, S6K,
and IKK (6–23). The relative contribution of these nega-
tive regulators to the progression of insulin resistance has
been extensively studied (6–24). However, insulin signal-
ing is likely to also be modulated by positive regulators. In
this study, we demonstrate that SH2B1 is a novel endoge-
nous insulin sensitizer.
SH2B1 is a member of the SH2B family of adapter
proteins that also includes SH2B2 (APS) and SH2B3 (Lnk).
SH2B1 and SH2B2 are expressed in multiple tissues,
including insulin target tissues (e.g., skeletal muscle, adi-
pose tissue, liver, and the brain); by contrast, SH2B3
expression is restricted to hematopoietic tissue (25,26).
Structurally, SH2B family members have an NH2-terminal
dimerization domain, a central pleckstrin homology do-
main, and a COOH-terminal Src homology 2 (SH2) domain.
The dimerization domain mediates homodimerization or
heterodimerization between different SH2B proteins (27).
SH2B1 and SH2B2 bind via their SH2 domains to a variety
of tyrosine phosphorylated proteins, including JAK2 and
insulin receptor, in cultured cells (28). Genetic deletion of
SH2B1 results in marked leptin resistance, obesity, insulin
resistance, and type 2 diabetes in mice, demonstrating that
SH2B1 is required for the maintenance of normal body
weight, insulin sensitivity, and glucose metabolism (29–
32). Surprisingly, SH2B2-null mice have normal body
weight and slightly improved insulin sensitivity (32,33),
suggesting that SH2B1 and SH2B2 have distinct functions
in vivo. However, it remains unclear whether SH2B1 cell
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insulin target tissues because systemic deletion of SH2B1
causes obesity, which may cause insulin resistance in
SH2B1-null mice.
We generated a mouse model in which recombinant
SH2B1 is speciﬁcally expressed in the brain of SH2B1-null
mice (TgKO) using transgenic approaches (31). Neuron-
speciﬁc restoration of SH2B1 corrects both leptin resis-
tance and obesity, suggesting that neuronal SH2B1
regulates energy balance and body weight by enhancing
leptin sensitivity (31). Consistent with these conclusions,
polymorphisms in the SH2B1 loci are linked to leptin
resistance and obesity in humans (34–36). In this work, we
demonstrate that deletion of SH2B1 in peripheral tissues
impairs insulin sensitivity independent of obesity in TgKO
mice. Moreover, we demonstrate that SH2B1 directly
promotes insulin responses by stimulating insulin receptor
catalytic activity and by protecting IRS proteins from
tyrosine dephosphorylation.
RESEARCH DESIGN AND METHODS
Animal studies. SH2B1 knockout and TgKO mice have been described
previously (29,31) and were backcrossed for six generations onto a C57BL/6
genetic background. Mice were housed on a 12-h light/dark cycle in the Unit
for Laboratory Animal Medicine at the University of Michigan and fed either
normal rodent diet (9% fat; Lab Diet) or high-fat diet (HFD; 45% fat; Research
Diets) ad libitum with free access to water. Fat content was measured by
dual-energy X-ray absorptiometry (Norland Medical System). Blood glucose
levels were determined using glucometers (Bayer Corp). Plasma insulin was
measured using a rat insulin enzyme-linked immunosorbent assay kit (Crystal
Chem). Glucose tolerance tests (GTT) (2 g D-glucose/kg of body weight) and
insulin tolerance tests (ITT) (1 IU/kg of body weight; Eli Lilly) were conducted
as previously described (29–31). To analyze insulin signaling, mice (fasted
16 h) were anesthetized with Averin (0.5 g of tribromoethanol and 0.25 g or
tert-amyl alcohol in 39.5 ml of water; 0.02 ml/g of body weight) and treated
with PBS or human insulin (3 units per mouse; Eli Lilly) via inferior vena cava
injection. Five minutes after stimulation, gastrocnemius muscles, liver, and
epididymal fat pads were dissected, frozen in liquid nitrogen, and stored at
80°C. Tissues were homogenized in ice-cold lysis buffer (50 mmol/l Tris HCl
[pH 7.5], 1.0% NP-40, 150 mmol/l NaCl, 2 mmol/l EGTA, 1 mmol/l Na3VO4, 100
mmol/l NaF, 10 mmol/l Na4P2O7, 1 mmol/l PMSF, 10 g/ml aprotinin, 10 g/ml
leupeptin), and extracts were immunoblotted or immunoprecipitated with
indicated antibodies. Animal protocols were approved by the University
Committee on Use and Care of Animals.
Cell lines and transfection. COS7 and HEK293 cells were grown in DMEM
supplemented with 5% bovine serum and transfected with indicated plasmids
using Lipofectamine 2000 (Invitrogen). Chinese hamster ovary (CHO
IR and
CHO
IR/IRS1) cells were cultured in Ham’s F-12 media supplemented with 8%
FBS. Cells were deprived of serum for 16 h in DMEM (COS7 and HEK293) or
F-12 (CHO) containing 0.6% BSA before being treated. Primary liver cells were
isolated from male mice (8 weeks) by perfusion of the liver with type II
collagenase (Worthington Biochem) and plated on collagen-coated plates in
M199 containing 10% FBS, 100 units/ml penicillin, and 100 g/ml streptomycin.
After 2 h, primary cells were rinsed in PBS and cultured for an additional 16 h
in Williams’ Medium E (Sigma) supplemented with 0.6% BSA, 100 units/ml
penicillin, and 100 g/ml streptomycin.
Immunoprecipitation and immunoblotting. Immunoprecipitation and im-
munoblotting were conducted as described previously (29,37). Proteins were
visualized using the Odyssey Infrared Imaging System (Li-Cor Biosciences) or
ECL (Amersham) and quantiﬁed using Odyssey 1.2 software (Li-Cor). Actin,
phosphoAkt (Thr
308), Akt, insulin receptor , Myc, Shc, and tubulin antibodies
were from Santa Cruz. The phosphotyrosine-speciﬁc antibody was from
Upstate. The AS160 antibody was from Millipore and phospho Akt substrate
antibody was from Cell Signaling. Phospho Akt (Ser
473) was from BioSource.
SH2B1 and IRS-1 antibodies have been described (14,37).
Insulin receptor kinase assay. Cells were serum deprived for 16 h, treated
with insulin, and solubilized in kinase lysis buffer (50 mmol/l Tris HCl [pH 7.5],
0.1% Triton X-100, 150 mmol/l NaCl, 1 mmol/l EDTA, 1 mmol/l Na3VO4,1
mmol/l PMSF, 10 g/ml aprotinin, 10 g/ml leupeptin). The insulin receptor
was precipitated with wheat germ agglutinin (WGA)-conjugated agarose
beads, washed three times in wash buffer (50 mmol/l Tris HCl [pH 7.5], 0.5
mol/l NaCl, 0.1% Triton X-100), and twice in kinase reaction buffer (20 mmol/l
HEPES [pH 7.6], 0.1% Triton X-100, 5 mmol/l MgCl2, 100 mol/l Na3VO4).
WGA-immobilized proteins were preincubated in kinase reaction buffer sup-
plemented with soluble glutathione S-transferase (GST) alone, GST-SH2B1, or
GST-SH2 fusion proteins at 37°C. GST-IRS-1 (5–10 g) and ATP (50 mol/l)
were added to initiate kinase reactions at 37°C. Reactions were stopped by
adding SDS-PAGE loading buffer, and reaction mixtures were boiled immedi-
ately. Proteins were separated by SDS-PAGE and immunoblotted with indi-
cated antibodies.
Dephosphorylation assays. Immunopuriﬁed proteins were washed in lysis
buffer and preincubated with GST-SH2B1 or GST (2 g) in phosphatase
reaction buffer (50 mmol/l Tris-HCl [pH 8.2], 100 nmol/l NaCl, 10 mmol/l
MgCl2, 1 mmol/l DTT) for 15 min at room temperature with constant mixing.
Alkaline phosphatase (New England Biolabs) was added at the indicated
concentration, and the mixtures were incubated an additional 30 min at room
temperature. Reactions were stopped by adding SDS-PAGE loading buffer and
mixtures were boiled immediately. Proteins were separated by SDS-PAGE and
immunoblotted with indicated antibodies.
Statistical analysis. Data are presented as means  SE. Differences between
groups were determined by two-tailed Student’s t tests or ANOVA. P  0.05
was considered signiﬁcant.
RESULTS
Loss of peripheral SH2B1 predisposes mice to HFD-
induced insulin resistance. We previously generated
SH2B1 transgenic (Tg) mice in which the expression of
recombinant SH2B1 is controlled by the neuron-speciﬁc
enolase promoter (31). Tg mice were crossed with SH2B1
knockout mice to generate SH2B1 transgenic/knockout
compound mutant (TgKO) mice. In TgKO mice, recombi-
nant SH2B1 is expressed in brain but not in other tissues,
including liver, muscle, and adipose tissue (31). Neuron-
speciﬁc restoration of SH2B1 in TgKO mice fully corrected
leptin resistance and obesity and largely rescued the
hyperglycemia and insulin resistance observed in SH2B1
null mice, indicating that neuronal SH2B1 indirectly regu-
lates insulin sensitivity and glucose metabolism by con-
trolling adiposity (31).
To determine whether loss of peripheral SH2B1 exacer-
bates dietary fat–induced insulin resistance, TgKO and
wild-type littermates (7 weeks) were fed HFD. Body
weight and adiposity were similar between wild-type and
TgKO mice fed HFD (Fig. 1A and B). However, fasting (16
h) blood glucose levels were 1.3-fold higher in TgKO mice
than in wild-type mice fed HFD for 16 weeks (Fig. 1C).
Fasting plasma insulin levels were twofold higher in TgKO
mice than in wild-type mice (Fig. 1D). To examine insulin
sensitivity, GTT and ITT were performed. Blood glucose
levels were 23–26% higher in TgKO mice than wild-type
mice 15 and 30 min after injection of D-glucose (Fig. 1E).
Exogenous insulin markedly reduced blood glucose in
wild-type but not in TgKO mice during ITT (Fig. 1F). These
results indicate that loss of peripheral SH2B1 exacerbates
HFD-induced insulin resistance, hyperglycemia, and glu-
cose intolerance independent of obesity.
Loss of peripheral SH2B1 impairs insulin signaling in
muscle, liver, and adipose tissue in HFD-fed mice. To
examine insulin signaling in skeletal muscle, liver, and
epididymal fat, mice (7 weeks) were fed HFD for 16 weeks
and treated with insulin or PBS vehicle. Insulin markedly
stimulated tyrosine phosphorylation of IRS-1 as well as
IRS-1 association with p85, the regulatory subunit of the
phosphatidylinositol 3-kinase, in skeletal muscle of wild-
type mice (Fig. 2A). Both IRS-1 phosphorylation and
IRS-1-p85 association were markedly reduced in TgKO
muscle (Fig. 2A). Loss of peripheral SH2B1 also decreased
insulin receptor autophosphorylation and impaired the
ability of insulin to stimulate Akt phosphorylation on
Thr
308 and Ser
473 in TgKO muscle (Fig. 2A). Insulin-
stimulated IRS-1 and Akt Thr
308 phosphorylation were
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(Fig. 2B).
Insulin signaling was also examined in liver and white
adipose tissue (WAT) from HFD-fed mice. Relative to
wild-type mice, basal IRS-1 phosphorylation was increased
in both liver and WAT in TgKO mice; insulin stimulated
IRS-1 phosphorylation in these tissues from wild-type but
not TgKO mice (Fig. 2C and E). Akt phosphorylation
(Ser
473) was also reduced in liver (Fig. 2D) and WAT (not
shown) in TgKO mice. AS160, a Rab-GAP, is an Akt-
substrate involved in GLUT4 vesicle trafﬁcking in adipo-
cytes (38,39). To measure AS160 phosphorylation, WAT
extracts were immunoprecipitated with anti–phospho-Ser/
Thr Akt substrate antibody and immunoblotted with
anti-AS160 antibody. Similar to IRS-1, basal AS160 phos-
phorylation was increased in adipose tissue from TgKO
mice (Fig. 2F); however, insulin failed to further stimulate
AS160 phosphorylation (Fig. 2F). Together, these data
indicate that peripheral SH2B1 increases insulin sensitivity
in mice by promoting insulin signaling, including the
activation of the IRS protein/phosphatidylinositol 3-ki-
nase/Akt pathway, in muscle, liver, and WAT.
SH2B1 cell autonomously promotes insulin signaling
via its SH2 domain. To determine whether endogenous
SH2B1 directly enhances insulin signaling, primary hepa-
tocyte cultures were prepared from wild-type and SH2B1
FIG. 1. Peripheral SH2B1 enhances insulin sensitivity in mice. A–F:
Wild-type (WT) and TgKO male mice (7 weeks) were fed a HFD. A:
Growth curve. B: Body fat content after 16 weeks on HFD. C: Fasting
(16 h) blood glucose levels and (D) plasma insulin levels after 16
weeks on HFD. E: GTT performed on mice fed HFD for 16 weeks. F: ITT
performed on mice fed HFD for 16 weeks. The number of mice is
indicated in parenthesis. *P < 0.05, **P < 0.01, ***P < 0.001.
FIG. 2. Deletion of peripheral SH2B1 attenuates insulin signaling in mice.
Wild-type (WT) and TgKO males (7 weeks) were fed a HFD for 16 weeks.
Mice were fasted for 16 h and treated with PBS or insulin (3 units per
mouse). Tissue extracts were prepared 5 min after stimulation. A: IRS-1
in muscle extracts was immunoprecipitated with anti–IRS-1 antibody
(IRS-1) and immunoblotted with anti-phosphotyrosine (pTyr) and
p85 antibodies. Insulin receptor in muscle extracts was immunoprecipi-
tated with IR and immunoblotted with pTyr. Muscle extracts were
immunoblotted with phospho-speciﬁc Akt antibodies against phospho-
Thr
308 (pThr
308) or phospho-Ser
473 (pSer
473) and Akt, respectively. B:
IRS-1 and Akt phosphorylation in (A) was quantiﬁed by densitometry and
normalized to total IRS-1 and Akt protein levels, respectively. C: Liver
extracts were immunoprecipitated with IRS-1 and immunoblotted with
pTyr. The same blots were reprobed with IRS-1. IRS-1 phosphorylation
was quantiﬁed and normalized to total IRS-1 protein levels. D: Liver
extracts were immunoblotted with pSer
473 and Akt. Ser
473 phosphory-
lation was quantiﬁed and normalized to total Akt protein levels. E:
Epididymal fat (WAT) extracts were immunoprecipitated with IRS-1
and immunoblotted with pTyr and reprobed with IRS-1. IRS-1 phos-
phorylation was normalized to total IRS-1 protein levels. F: WAT extracts
were immunoprecipitated with PAS (anti–phospho-Ser/Thr Akt sub-
strate) and immunoblotted with AS160. Extracts were also immunoblot-
ted with tubulin. Three animals were examined for each condition. *P <
0.05, **P < 0.01, ***P < 0.001.
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detected in wild-type but not in knockout hepatocytes as
expected (Fig. 3A). Insulin stimulated tyrosine phosphor-
ylation of insulin receptor and IRS-1, IRS-1 association
with p85, and phosphorylation of Akt in wild-type hepato-
cytes; however, insulin receptor autophosphorylation,
IRS-1 phosphorylation, IRS-1 association with p85, and Akt
phosphorylation were all reduced in knockout hepato-
cytes (Fig. 3A). Interestingly, SH2B1 deﬁciency impaired
IRS-1 phosphorylation to a greater extent than insulin
receptor autophosphorylation. In HEK293 cells, overex-
pression of SH2B1 markedly increased insulin-stimulated
tyrosine phosphorylation of IRS-1; in contrast, a SH2B1
mutant in which the SH2 domain is disrupted because of
replacement of Arg
555 with Glu (R555E) functioned as a
dominant negative to inhibit IRS-1 phosphorylation (Fig.
3B). To further assess the role of the SH2 domain of
SH2B1, IRS-1 and insulin receptor were coexpressed with
N504, an NH2-terminal truncated form of rat SH2B1
(amino acids 504–670) that contained the entire SH2
domain and a minimal number of adjacent amino acids.
N504 also promoted IRS-1 phosphorylation in insulin-
treated cells (Fig. 3C). These data suggest that the SH2
domain of SH2B1 is not only required but also sufﬁcient to
promote insulin receptor–mediated phosphorylation of
IRS-1.
To determine whether SH2B1 also promotes phosphor-
ylation of other IRSs, Shc was coexpressed with SH2B1 or
N504. SH2B1 and N504 enhanced insulin stimulation of
Shc phosphorylation to similar levels (Fig. 3D). By con-
trast, SH2B1 stimulated IRS-1 phosphorylation to a higher
level than did N504 (Fig. 3C), suggesting that SH2B1
promotes phosphorylation of IRS-1 and Shc by different
mechanisms.
SH2B1 stimulates insulin receptor catalytic activity
through the binding of its SH2 domain to Tyr
1158 in
insulin receptor. SH2B1 directly binds via its SH2 do-
main to Tyr
1158 within the activation loop of insulin
receptor (40,41). To test whether this interaction modu-
lates insulin receptor activation, CHO
IR cells, which stably
express insulin receptor, were treated with insulin, and
active insulin receptor was puriﬁed using WGA-conjugated
agarose beads (42). Insulin receptor was then preincu-
bated with puriﬁed GST-SH2B1 fusion protein and subse-
quently subjected to in vitro kinase assays using GST-IRS-1
fusion protein as substrate. Tyrosine phosphorylation of
GST-IRS-1 was measured by immunoblotting with anti–
phospho-tyrosine antibodies. GST-SH2B1, but not GST
alone, dose-dependently stimulated insulin receptor ki-
nase activity as indicated by increased phosphorylation of
GST-IRS-1 (Fig. 4A). In similar experiments, a GST-SH2
fusion protein prepared by fusing the SH2 domain (amino
acids 524–670 of SH2B1) to GST was preincubated with
WGA-puriﬁed insulin receptor in vitro kinase assays. The
SH2 domain of SH2B1 was sufﬁcient to enhance insulin
receptor catalytic activity, stimulating IRS-1 phosphoryla-
tion by 66% (Fig. 4B). Additionally, the SH2 domain of
SH2B1 also promoted the catalytic activity of insulin
receptor immunopuriﬁed with an anti–phospho-tyrosine
antibody, increasing IRS-1 substrate phosphorylation by
79% (Fig. 4C).
To determine whether Tyr
1158 in insulin receptor is
involved in SH2B1 stimulation of insulin receptor activity,
Tyr
1158 was replaced with Phe (Y1158F). COS7 cells were
transiently transfected with insulin receptor or Y1158F
and treated with insulin. Insulin stimulated autophosphor-
FIG. 3. SH2B1 directly promotes insulin signaling in cells via its SH2
domain. A: Primary hepatocyte cultures were prepared from wild-type
(WT) or knockout (KO) mice (8 weeks) and treated with 100 nmol/l
insulin for 10 min. Panel 1: Cell extracts were immunoprecipitated
with SH2B1 and immunoblotted with SH2B1. Panels 2 and 3: Cell
extracts were immunoprecipitated with IR and immunoblotted with
pTyr and IR. Panels 4 and 5: Cell extracts were immunoprecipitated
with IRS-1 and immunoblotted with pTyr or p85. Panels 6 and 7:
Cell extracts were immunoblotted with pSer
473 and Akt. B: IRS-1
and insulin receptor were transiently coexpressed with empty vector
(CON), Myc-tagged SH2B1, or R555E plasmids in HEK293 cells. Cells
were treated with 100 nmol/l insulin for 10 min and extracts were
immunoblotted with indicated antibodies. C: IRS-1 and insulin recep-
tor were transiently coexpressed with empty vector (CON), Myc-
tagged SH2B1, or N504 plasmids in HEK293 cells. Cells were treated
with 100 nmol/l insulin for 10 min and extracts were immunoblotted
with indicated antibodies. IRS-1 phosphorylation was normalized to
total IRS-1 protein levels. D: Shc and insulin receptor were transiently
coexpressed with empty vector (CON), Myc-tagged SH2B1, or N504
plasmids in HEK293 cells. Cells were treated with 100 nmol/l insulin
for 10 min and extracts were immunoblotted with indicated antibodies.
Shc phosphorylation was normalized to total Shc protein levels. *P <
0.05, **P < 0.01, ***P < 0.001.
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autophosphorylation was reduced (Fig. 4D). Y1158F phos-
phorylated IRS-1 in response to insulin (data not shown),
indicating that Y1158F retains the ability to be activated
and to phosphorylate its substrates. Insulin receptor and
Y1158F were puriﬁed using WGA-beads, preincubated
with GST-SH2B1, and subjected to in vitro kinase assays.
SH2B1 stimulated insulin receptor kinase activity by ap-
proximately ﬁvefold; however, SH2B1 was unable to stim-
ulate Y1158F catalytic activity (Fig. 4E). Taken together,
these data suggest that the physical interaction between
the SH2 domain of SH2B1 and Tyr
1158 in insulin receptor is
required and sufﬁcient for stimulation of insulin receptor
catalytic activity.
SH2B1 protects IRS proteins against tyrosine de-
phosphorylation. SH2B1 directly binds to IRS-1 and
IRS-2 in vitro (37), and insulin stimulated coimmunopre-
cipitation of SH2B1 with IRS-1 in cells (Fig. 5A). To
determine whether this physical interaction inhibits IRS-1
dephosphorylation by phosphatases, CHO
IR/IRS-1 cells,
which stably express insulin receptor and IRS-1, were
stimulated with insulin to promote tyrosine phosphoryla-
tion of IRS-1. Phosphorylated IRS-1 was immunopuriﬁed,
preincubated with GST or GST-SH2B1, and subjected to in
vitro dephosphorylation assays. IRS-1 bound to GST-
SH2B1 but not to GST (data not shown). Alkaline
phosphatase dose-dependently dephosphorylated IRS-1
on tyrosines in the GST-pretreated samples; in contrast,
alkaline phosphatase was unable to dephosphorylate
SH2B1-bound IRS-1 (Fig. 5B). Insulin also promoted the
association of SH2B1 with IRS-2, and SH2B1 similarly
inhibited tyrosine dephosphorylation of IRS-2 (data not
shown).
To determine whether SH2B1 inhibits IRS-1 dephos-
phorylation in cells, IRS-1 was coexpressed with PTP1B (a
protein tyrosine phosphatase) in the absence or presence
of SH2B1. PTP1B dephosphorylated IRS-1, and SH2B1
dose-dependently attenuated the ability of PTP1B to de-
phosphorylate IRS-1 (Fig. 5C). To determine whether
SH2B1 is able to promote IRS-1 phosphorylation without
stimulating insulin receptor kinase activity, Y1158F was
coexpressed with SH2B1. Although SH2B1 was unable to
stimulate Y1158F kinase activity (Fig. 4E), SH2B1 still
markedly enhanced tyrosine phosphorylation of IRS-1 in
Y1158F-expressing cells (Fig. 5D). Thus, SH2B1 is likely to
augment Y1158F-mediated phosphorylation of IRS-1 by
inhibiting IRS-1 dephosphorylation by endogenous protein
phosphatase(s).
To determine whether the SH2B1-IRS interaction steri-
cally inhibits the binding of IRS proteins to phosphatidyl-
inositol 3-kinase, IRS-1 and Y1158F were coexpressed with
or without SH2B1 in HEK293 cells, and IRS-1-p85 associ-
ation was examined by coimmunoprecipitation assays.
Insulin stimulated coimmunoprecipitation of IRS-1 with
p85, the regulatory subunit of phosphatidylinositol 3-ki-
nase; importantly, SH2B1 markedly enhanced insulin-stim-
ulated p85 binding to IRS-1 (Fig. 5E). These data indicate
that the SH2B1-IRS interaction does not interfere with
IRS-phosphatidylinositol 3-kinase interaction but rather
increases the IRS-phosphatidylinositol 3-kinase associa-
FIG. 4. SH2B1 directly enhances insulin receptor activity in vitro. A:
CHO
IR cells were treated without or with 100 nmol/l insulin for 10 min.
Insulin receptor was puriﬁed with WGA-agarose beads, preincubated
with indicated amounts of GST or GST-SH2B1 fusion protein and
subjected to in vitro kinase assays with GST-IRS-1 as substrate for 10
min. Reaction mixtures were immunoblotted with pTyr, IRS-1 or
IR. B: WGA-puriﬁed insulin receptor was preincubated with GST or
GST-SH2 fusion protein (5 g) and subjected to in vitro kinase assays
with GST-IRS-1 protein (amino acids 526–859 of rat IRS-1) as sub-
strate for 10 min. IRS-1 phosphorylation was quantiﬁed by densitom-
etry and normalized to total GST-IRS-1 levels. C: CHO
IR cells were
treated without or with 100 nmol/l insulin for 10 min. Cell extracts
were immunoprecipitated with pTyr. pTyr-immunopuriﬁed insulin
receptor was preincubated with GST or GST-SH2 fusion protein
(amino acids 524–670) (5 g) and subjected to in vitro kinase assays
with GST-IRS-1 as substrate for 10 min. Reaction mixtures were
immunoblotted with indicated antibodies and IRS-1 phosphorylation
was quantiﬁed and normalized to total GST-IRS-1 levels. D: Wild-type
insulin receptor or Y1158F was expressed in COS7 cells. Cells were
treated with 100 nmol/l insulin for 10 min. Cell extracts were immu-
noblotted with pTyr or IR. E: Wild-type insulin receptor or Y1158F
was expressed in COS7 cells and treated with insulin. Wild-type insulin
receptor or Y1158F was puriﬁed with WGA-agarose beads, preincu-
bated with GST or GST-SH2B1 fusion protein (5 g), and subjected to
in vitro kinase assays with GST-IRS-1 as substrate for 10 min. GST-
IRS-1 phosphorylation was normalized to total GST-IRS-1 protein
levels. *P < 0.05, **P < 0.01.
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these observations, SH2B1 also enhanced insulin-stimu-
lated, Y1158F-mediated Akt phosphorylation (Fig. 5F).
Collectively, these data suggest that, in addition to enhanc-
ing insulin receptor catalytic activity via binding to Tyr
1158,
SH2B1 also promotes activation of the IRS protein/phos-
phatidylinositol 3-kinase/Akt pathway by inhibiting IRS
dephosphorylation.
DISCUSSION
Insulin resistance is the primary risk factor for various
metabolic diseases, including type 2 diabetes, nonalco-
holic fatty liver disease, dyslipidemia, and cardiovascular
disease. The molecular mechanisms underlying insulin
resistance are extremely complex and not completely
understood. It is commonly accepted that impairments in
insulin signal transduction play a key role in the develop-
ment of insulin resistance. We previously observed that
insulin signaling is enhanced by SH2B1 (29). SH2B1 over-
expression increases insulin receptor autophosphoryla-
tion and tyrosine phosphorylation of IRS-1 and IRS-2 in
cultured cells (29,43). Similar observations were indepen-
dently reported by two other groups (44,45). Additionally,
we showed that genetic deletion of SH2B1 results in
severe insulin resistance and type 2 diabetes in mice (29).
However, SH2B1-null mice are also severely obese be-
cause of leptin resistance (30–32), raising the possibility
that insulin resistance may be secondary to obesity in
SH2B1-null mice. Therefore, it was unclear whether pe-
ripheral SH2B1 directly regulates insulin sensitivity in
insulin target tissues in vivo.
We generated TgKO mice that express SH2B1 only in the
brain but not in peripheral tissues (e.g., liver, muscle, and
adipose tissue). Body weight was similar between TgKO
and wild-type littermates fed HFD, consistent with our
previous conclusion that neuronal SH2B1 controls energy
balance and body weight by enhancing leptin sensitivity in
the hypothalamus (31). In the current study, we demon-
strated that loss of peripheral SH2B1 markedly impaired
insulin sensitivity independent of body weight. TgKO mice
developed hyperglycemia, hyperinsulinemia, and glucose
intolerance to a greater extent than wild-type littermates
fed HFD. The ability of exogenous insulin to reduce blood
glucose and to stimulate insulin receptor autophosphory-
lation and phosphorylation of IRS proteins and Akt in
muscle, liver, and adipose tissue was signiﬁcantly reduced
in TgKO mice. These results suggest that peripheral SH2B1
serves as an endogenous insulin sensitizer. Insulin signal-
ing has been shown to be attenuated by multiple intracel-
lular signaling molecules (e.g., PTP1B, Grb10, Grb14,
SOCS1, SOCS3, JNK, PKC, S6K, and IKK) that contrib-
ute to the development of insulin resistance (6–24). Our
data suggest that insulin sensitivity is controlled by a
balance between these negative regulators and SH2B1 in
insulin target cells.
SH2B1 promotes insulin signaling by stimulating insulin
receptor catalytic activity. SH2B1 binds via its SH2 domain
to phospho-Tyr
1158 in the activation loop of insulin recep-
tor (40,41). We showed that bacteria-derived SH2B1 mark-
edly increased the ability of puriﬁed insulin receptor to
tyrosyl phosphorylate IRS-1 in vitro. In contrast, SH2B1
was unable to stimulate the catalytic activity of Y1158F, an
FIG. 5. SH2B1 protects IRS-1 from dephosphorylation. A: IRS-1 and
SH2B1 were transiently expressed in HEK293 cells. Cell extracts were
immunoprecipitated with SH2B1 and immunoblotted with IRS-1 and
SH2B1. B: CHO
IR/IRS-1 cells were stimulated with 100 nmol/l insulin
for 10 min. IRS-1 was immunoprecipitated with IRS-1, preincubated
with GST or GST-SH2B1 (2 g), and subjected to in vitro dephosphor-
ylation assays with indicated amounts of alkaline phosphatase for 30
min. Reaction mixtures were immunoblotted with pTyr and IRS-1. C:
Insulin receptor and IRS-1 were transiently expressed with PTP1B (0.1
g) and increasing amounts of Myc-tagged SH2B1 (0–0.8 g). Cells
were treated with 100 nmol/l insulin for 10 min and extracts were
immunoblotted with indicated antibodies. D: IRS-1 was expressed with
insulin receptor or Y1158F in the absence (CON) or presence of SH2B1
in HEK293 cells. Cells were treated with 100 nmol/l insulin for 10 min
and extracts were immunoblotted with indicated antibodies. E: IRS-1
(1 g) and Y1158F (1 g) plasmids were transiently cotransfected with
or without SH2B1 plasmids (0.8 g) in HEK293 cells. Cells were
deprived of serum overnight 48 h after transfection and treated with
100 nmol/l insulin for 10 min. Cell extracts were immunoprecipitated
with IRS-1 and immunoblotted with p85 and IRS-1. Extracts were
also immunoblotted with indicated antibodies. F: IRS-1 and Y1158F
were coexpressed with or without SH2B1. Cells were treated with 100
nmol/l insulin for 10 min and extracts were immunoblotted with
indicated antibodies.
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In cells, SH2B1 overexpression promotes insulin receptor
autophosphorylation as well as insulin receptor phosphor-
ylation of its substrates (e.g., IRS-1, IRS-2, and Shc).
Conversely, deletion of endogenous SH2B1 impaired insu-
lin stimulation of insulin receptor autophosphorylation
and IRS-1 phosphorylation in primary hepatocyte cultures.
Consistent with these observations, SH2B1 complexes,
which are immunoprecipitated from cell extracts, report-
edly promote insulin receptor autophosphorylation by
reducing the Km for ATP (45). The same report also
concluded that SH2B1 dimerization was required for its
stimulation of insulin receptor autophoshorylation, be-
cause treatment of cells with dimerization domain peptide
mimetics inhibited insulin receptor autophosphorylation
and downstream pathways (45). However, the report did
not provide evidence showing that the mimetics disrupted
SH2B1 dimerization. In contrast, we observed that the SH2
domain alone was sufﬁcient to stimulate insulin receptor
catalytic activity in vitro. Moreover, N504, an NH2-termi-
nal truncated SH2B1 containing the intact SH2 domain but
completely lacking both dimerization and pleckstrin ho-
mology domains, still markedly enhanced insulin-stimu-
lated tyrosine phosphorylation of both IRS-1 and Shc.
Conversely, R555E, a SH2B1 mutant with a defective SH2
domain, inhibited insulin signaling as a dominant negative
mutant. These data indicate that the SH2 domain of SH2B1
is both required and sufﬁcient to stimulate insulin receptor
kinase activity. Because Tyr
1158 phosphorylation occurs
early in the activation of the insulin receptor kinase
(42,46,47), binding of the SH2 domain of SH2B1 to phospho-
Tyr
1158 may stabilize insulin receptor in an active confor-
mation. Alternatively, SH2B1-insulin receptor interaction
may facilitate insulin receptor binding to its substrates.
Insulin stimulated the binding of SH2B1 to IRS-1 or
IRS-2. Importantly, SH2B1 directly inhibited tyrosine de-
phosphorylation of IRS-1 and IRS-2 by recombinant phos-
phatase in vitro and by PTP1B in cultured cells. Although
unable to stimulate Y1158F catalytic activity, SH2B1 still
enhanced Y1158F-mediated phosphorylation of IRS-1 in
cultured cells, presumably by inhibiting IRS-1 dephosphor-
ylation by endogenous tyrosine phosphatase(s). Consis-
tent with these observations, deletion of endogenous
SH2B1 impaired tyrosine phosphorylation of IRS-1 to a
greater extent than insulin receptor autophosphorylation
in primary hepatocyte cultures. Together, these data sug-
gest that the SH2B1-IRS physical interaction inhibits IRS
dephosphorylation by tyrosine phosphatases. Interest-
ingly, the SH2B1-IRS interaction did not inhibit the ability
of phosphorylated IRS proteins to bind to p85, the regula-
tory subunit of phosphatidylinositol 3-kinase; in contrast,
it enhanced insulin-stimulated IRS-p85 association and
subsequent Akt phosphorylation and activation, presum-
ably by protecting IRS proteins against dephosphorylation.
These data suggest that SH2B1 does not compete with p85
for the same binding sites in IRS proteins, and that the
SH2B1-IRS interaction does not sterically interfere with
the IRS-p85 interaction. Therefore, the SH2B1-IRS interac-
tion may selectively block IRS interaction with tyrosine
phosphatases, thereby inhibiting IRS dephosphorylation.
Alternatively, the SH2B1-IRS interaction may alter IRS
conformation so that multiple tyrosine phosphorylation
sites, in addition to SH2B1-bound site(s), are resistant to
dephosphorylation, but still retain their ability to bind to
downstream signaling molecules and activate downstream
pathways including the phosphatidylinositol 3-kinase/Akt
pathway.
In conclusion, SH2B1 appears to promote insulin sensi-
tivity in animals by multiple mechanisms (Fig. 6). Neuro-
nal SH2B1 increases insulin sensitivity indirectly by
reducing adiposity (31). In muscle, liver, and adipose
tissue, SH2B1 binds to insulin receptor and stimulates
insulin receptor catalytic activity to globally activate path-
ways downstream of insulin receptor. SH2B1 binds to both
IRS-1 and IRS-2 and protects IRS proteins from tyrosine
dephosphorylation, augmenting and/or prolonging IRS
protein-mediated pathways. In addition, SH2B1 forms
dimers, and each SH2B1 molecule in a SH2B1 dimer may
simultaneously bind to insulin receptor and IRS-1 (or
IRS-2), thereby stabilizing insulin receptor/IRS-1 (or insu-
lin receptor/IRS-2) complexes. Therefore, SH2B1 and mol-
ecules that mimic these functions of SH2B1 are potential
therapeutic targets for the treatment of obesity and/or type
2 diabetes.
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